🇺🇸 FDA
Company

Centessa

Centessa Pharmaceuticals plc

CNTA pharma USA

Quick answer

Centessa is a pharma company (CNTA) headquartered in ALTRINCHAM, CHESHIRE, X0, USA with 12 tracked pipeline programs.

Pipeline (12)

project

Lixivaptan

Autosomal Dominant Polycystic Kidney

Phase 3 · small_molecule · terminated

1 trials project

Lixivaptan

Polycystic Kidney Disease, Adult

Phase 3 · small_molecule · terminated

2 trials project

SerpinPC

Hemophilia a

Phase 3 · small_molecule · completed

3 trials project

cleminorexton

Narcolepsy Type 1

Phase 3 · small_molecule · active

1 trials project

Imgatuzumab

Cutaneous Squamous Cell Carcinoma

Phase 2 · small_molecule · terminated

1 trials project

LB101

Advanced Solid Tumor

Phase 2 · small_molecule · terminated

1 trials project

ORX750

Narcolepsy Type 1

Phase 2 · small_molecule · active

2 trials project

SerpinPC

Hemophilia B with Inhibitor

Phase 2 · small_molecule · terminated

1 trials project

CBS001

Chronic Inflammatory Disease

Phase 1 · small_molecule · terminated

1 trials project

ORX142 Tablets

Excessive Daytime Sleepiness

Phase 1 · small_molecule · active

1 trials project

ORX489 Tablets

Healthy Adult Male and Female Volunteers

Phase 1 · small_molecule · active

1 trials project

ZF874

Alpha1 Anti-Trypsin Deficiency

Phase 1 · small_molecule · terminated

1 trials

Patents (7)

patent

US 12421310

CD47 binding agents

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12415861

Anti C-MET antibodies

Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12365672

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12291507

Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12286402

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12227580

Antigen binding molecules that bind LIGHT

Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12221422

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)